vimarsana.com
Home
Live Updates
Vifor International AG (CSL Vifor): Topline Results from Two
Vifor International AG (CSL Vifor): Topline Results from Two
Vifor International AG (CSL Vifor): Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment
Related Keywords
Switzerland ,
Australia ,
Melbourne ,
Victoria ,
Steve Pascoe ,
Fresenius Medical Care ,
Dual Endothelin Angiotensin Receptor Antagonist ,
Senior Vice President ,
Therapeutic Area Strategy ,
Efficacy Endpoints ,
Two Year Exploratory Endpoints ,
Travere Therapeutics ,
Vifor Fresenius Medical Care Renal Pharma ,
Vifor ,
Nternational ,
Topline ,
Results ,
Rom ,
Ear ,
Primary ,
Efficacy ,
Ndpoint ,
Pivotal ,
Hase ,
Duplex ,
Study ,
Sparsentan ,
Ocal ,
Egmental ,
Glomerulosclerosis ,